Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Other illness

• History of anaphylactic reactions to products containing indocyanine green
• History of allergy to any of the components of ZOPOCIANINE:
  • 2-\[3-(1,3-dicarboxypropyl)ureido\] pentanedioic acid (DUPA)
  • Polyethylene glycol-dipeptide linker
  • Chlorodye
• Significant acute or chronic medical, neurologic, or illness in the subject that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study

Lab values

• Impaired renal or hepatic function:
  • Renal: creatinine clearance (eGFR) \< 50 mL/min
  • Hepatic: total bilirubin \> 2 × upper limit of normal or ALT/AST \> 3 × upper limit of normal.
• Patients with QTc interval ≥ 470 msec per electrocardiogram (ECG) at screening.

Other

• The surgeon plans to perform an extraperitoneal approach

• Provision of signed and dated informed consent and HIPAA form
• Male subjects 18 years of age and older
• Known primary prostate cancer and Grade Group 3 to 5 (≥ cT3) or one or more of the following:
  • Suspected extraprostatic disease (EPD) (extracapsular extension (ECE) and/or seminal vesicle infiltration (SVI)),
  • 3 or more biopsy cores of grade group 3-5;
  • Suspected lymph node metastasis (clinical stage cN1, or by magnetic resonance imaging (mriN+), or by Prostate Specific Membrane Antigen positron emission tomography (PSMA PET+));
• Planned to undergo a standard of care robotic prostatectomy and lymph node dissection
• Ability to understand the requirements of the study and agree to abide by the study restrictions and to return for the required assessments
• Agree to use a medically acceptable method of birth control (e.g., spermicide in conjunction with a barrier such as a condom) or sexual abstinence for the duration of the study, including through final study visit (6 weeks) after the dose of study drug. Sperm donation is prohibited during the study and for 3 months after the dose of study drug. Female partners must use hormonal or barrier contraception unless postmenopausal or abstinent.